Short-hairpin RNA-mediated Heat shock protein 90 gene silencing inhibits human breast cancer cell growth in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 421, Issue 2, 2012, Pages 396-402

  Zuo, Keqiang ^a   Li, Dan ^a   Pulli, Benjamin ^b   Yu, Fei ^a   Cai, Haidong ^a   Yuan, Xueyu ^a   Zhang, Xiaoping ^a   Lv, Zhongwei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Breast cancer; Heat shock protein 90; MCF 7 cell; Short hairpin RNA

Indexed keywords

HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE REGULATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84860451403     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.032     Document Type: Article

References (33)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
3. Linos E., Spanos D., Rosner B.A., Linos K., Hesketh T., Qu J.D., Gao Y.T., Zheng W., Colditz G.A. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J. Natl. Cancer Inst. 2008, 100:1352-1360.
4. Ciocca D.R., Vargas-Roig L.M. Hsp27 as a prognostic and predictive factor in cancer. Prog. Mol. Subcell Biol. 2002, 28:205-218.
5. Beliakoff J., Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004, 15:651-662.
6. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
7. Neckers L., Lee Y.S. Cancer: the rules of attraction. Nature 2003, 425:357-359.
8. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75:271-294.
9. Rutherford S.L., Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998, 396:336-342.
10. Sangster T.A., Salathia N., Lee H.N., Watanabe E., Schellenberg K., Morneau K., Wang H., Undurraga S., Queitsch C., Lindquist S. HSP90-buffered genetic variation is common in Arabidopsis thaliana. Proc. Natl. Acad. Sci. USA 2008, 105:2969-2974.
11. Wang S.L., Yao H.H., Qin Z.H. Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin. Biol. Ther. 2009, 9:1357-1368.
12. Lacroix M., Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 2004, 83:249-289.
13. Jin L., Xiao C.L., Lu C.H., Xia M., Xing G.W., Xiong S., Liu Q.Y., Liu H., Li Y.C., Ge F., Wang Q.D., He Q.Y., Wang Y.F. Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Lett. 2009, 583:1859-1866.
14. Yang Y.P., Kuo H.S., Tsai H.D., Peng Y.C., Lin Y.L. The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone. Breast Cancer Res. 2005, 7:R19-R27.
15. Cappello F., David S., Rappa F., Bucchieri F., Marasa L., Bartolotta T.E., Farina F., Zummo G. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 2005, 5:139.
16. Darby J.F., Workman P. Chemical biology: many faces of a cancer-supporting protein. Nature 2011, 478:334-335.
17. Strzelczyk J.K., Krakowczyk L., Kasperczyk J., Strzelczyk J., Zalewska-Ziob M. Wiczkowski, The concentration of HSP 27 in tumour and adjacent distal mucosa in colorectal adenocarcinoma. Przegl. Lek. 2011, 68:263-268.
18. Khong T., Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol. Cancer Ther. 2011, 10:1909-1917.
19. Sims J.D., McCready J., Jay D.G. Extracellular heat shock protein (Hsp)70 and Hsp90alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 2011, 6:e18848.
20. Wei L., Liu T.T., Wang H.H., Hong H.M., Yu A.L., Feng H.P., Chang W.W. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappaB. Breast Cancer Res. 2011, 13:R101.
21. Sankhala K.K., Mita M.M., Mita A.C., Takimoto C.H. Heat shock proteins: a potential anticancer target. Curr. Drug Targets 2011, 12:2001-2008.
22. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206:149-157.
23. Mehta P.P., Whalen P., Baxi S.M., Kung P.P., Yamazaki S., Yin M.J. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin. Cancer Res. 2011, 17:5432-5442.
24. Palacios C., Lopez-Perez A.I., Lopez-Rivas A. Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAIL-induced apoptosis in breast tumor cells. Cancer Lett. 2010, 287:207-215.
25. Arya R., Mallik M., Lakhotia S.C. Heat shock genes - integrating cell survival and death. J. Biosci. 2007, 32:595-610.
26. Chen G., Cao P., Goeddel D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell 2002, 9:401-410.
27. Stokoe D., Stephens L.R., Copeland T., Gaffney P.R., Reese C.B., Painter G.F., Holmes A.B., McCormick F., Hawkins P.T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277:567-570.
28. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87:619-628.
29. Sato S., Fujita N., Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 2000, 97:10832-10837.
30. Basso A.D., Solit D.B., Chiosis G., Giri B., Tsichlis P., Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 2002, 277:39858-39866.
31. Chandarlapaty S., Sawai A., Ye Q., Scott A., Silinski M., Huang K., Fadden P., Partdrige J., Hall S., Steed P., Norton L., Rosen N., Solit D.B. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 2008, 14:240-248.
32. Burnett J.C., Rossi J.J., Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 2011, 6:1130-1146.
33. Manjunath N., Wu H., Subramanya S., Shankar P. Lentiviral delivery of short hairpin RNAs. Adv. Drug Deliv. Rev. 2009, 61:732-745.